PureTech Health plc
PRTC · Price history
Company & revenue
About PureTech Health plc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms.
How they make money
PureTech Health operates a hub-and-spoke biotherapeutics model where it identifies, shapes, and de-risks therapeutic candidates through dedicated subsidiary structures. The company generates value by advancing these programs through critical R&D stages and scaling them with external capital, aiming for monetization through licensing, partnerships, or equity exits.
Products & services
The company develops a pipeline of therapeutic candidates focused on neurology, immunology, and oncology, utilizing a hub-and-spoke R&D platform to advance programs from discovery to clinical development.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
48
Weak
Financial Strength
11
Business Quality / Moat
100
Management
40
Growth Quality
73
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
22
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
36/100
Building Historical Record
Model Score 36/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for PRTC
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can PRTC maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can PRTC fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PRTC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PRTC to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PRTC's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
22
Market Cap
$4.23B
P/E Ratio
-0.6
EPS
$-26.80
52-Week High
$19.92
52-Week Low
$14.50
Beta
0.76
Analyst Target
$57.00
Shares Outstanding
243.4M
Total Revenue
$9.0M
Total Debt
$19.6M
Dividend
No current dividend
Liquidation Value / Share
$1.26
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for PRTC
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on PRTC.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Capital-efficient R&D hub-and-spoke model.
- +Validated pharmacology focus.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Vulnerability to global economic factors and geo-political actions.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
25
Oct 1, 2026
Change
Unchanged
Current Score
25
Oct 15, 2026
Category Changes
PRTC score was unchanged.
Projected Score
Projected Score
15
Projected Change
-10.0 points
Preliminary comparable-period financial changes suggest decline of approximately 10.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$17.38
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $4.7M | $4.8M | $3.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $26.5M | $0.00 | $3.6M | $4.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$17.6M | $4.7M | $1.3M | -$1.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $110.7M | $45.7M | $54.3M | $96.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $72.4M | $20.7M | $27.5M | $48.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $216.8M | $103.2M | $140.4M | $54.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$57.6M | -$61.8M | $37.4M | -$11.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$234.4M | -$98.5M | -$136.1M | -$146.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $55.7M | $45.8M | $10.0M | $13.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$86.9M | -$110.9M | $23.8M | -$36.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$4.8M | -$842K | -$4.0M | $30.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$56.0M | -$109.7M | $53.5M | -$65.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-26.80 | $-46.00 | $2.00 | $-2.40 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 2.41M | 2.41M | 26.97M | 27.63M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 2.41M | 2.41M | 26.97M | 27.63M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.8M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$26.90
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-12.4%
Cash Change
-9.5%
Margin Change
-4685.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 30.5%. EPS declined 868.6%. Cash declined 9.5%. Total debt declined 12.4%. Net income margin declined by 4685.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyRumor Mill · PRTC
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial